Digg It - Finance

As a continuation of the earlier article into the movers and shakers of the UK banking sector, we hereby list the financial details of mor

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

e of the UK’s largest financial institutions.

Name : HBOS

Value Of Group : ?42.02 billion

Profits in 2005 : ?3.23 billion

HBOS is a me

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

ger of the old Halifax Building Society and Bank of Scotland, which was a particularly good fit with few areas of overlap. The group now

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

has a good mixture of the financial power of Halifax and the cost control expertise of Bank of Scotland. As both were predominately UK ba

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

ed, there are plans for substantial overseas investment in the future.

Click here for the up to date share price and financial informatio

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

.

Name : Lloyds Bank

Value Of Group : ?33.4 billion

Profits in 2005 : ?2.493 billion

Lloyds Bank is in a similar situation to Barclays

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

Bank, in that it seems to have trouble keeping up with the newer entrants to the market. Again, the Bank also suffered from the historic

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

third world debt situation, and was forced to write off billions in irrecoverable loans. While still a powerhouse in the UK, the group ha

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

also been mentioned as a possible bid target - but whether anything materialises is another question.

Click here for the up to date shar

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

e price and financial information.

Name : Standard Chartered

Value Of Group : ?20.4 billion

Profits in 2005 : ?1.946 billion

Historica

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

ly strong in the Far East, Standard Chartered is still a major presence in that area of the world - although there is a wider spread to th

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

business these days. The group has been surrounded by takeover speculation for the last 20 years, with a number of shareholders retaining

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

substantial stakes. Its seems inevitable that the group will go at some stage.

Click here for the up to date share price and financial

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

nformation.

Name : Alliance & Leicester

Value Of Group : ?4.91 billion

Profits in 2005 : ?389 million

While one of the smaller UK offe

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

ings on the banking scene, Alliance and Leicester has built itself a strong niche market, with particular expertise in the area of mortgag

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

es. Born from the old Alliance and Leicester building society, the group have moved ahead since flotation on the stockmarket. While not

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

uite into the big league as yet, there are high hopes for future growth.

Click here for the up to date share price and financial informat

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

on.

The UK has one of the most developed banking sectors of the world, and a number of groups with large financial muscle. Recently ther

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

e have signs of unhappiness amongst the UK consumer as the banks see their profits grow and grow. While they have been riding on the cres

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

of a wave of late, there are signs that the economy is slowing, and this is normally an indication that the banks are in for a rocky time

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.diggit.org.ua/article/89620/diggit-UK-Finance-Who-Makes-The-Money--Part-Two.html">UK Finance: Who Makes The Money? Part Two</a>

BB link (for phorums):
[url=http://www.diggit.org.ua/article/89620/diggit-UK-Finance-Who-Makes-The-Money--Part-Two.html]UK Finance: Who Makes The Money? Part Two[/url]

Even though these adverts are routine and limited in style, you can still use striking words or phrases.

But imagine the irony: People come online today and expect to achieve the success of those who started it all the next day. People don't even give themselves time to understand what anything means before they begin to pull their cards and waste so much hard earned cash. It makes me sick.

Directory Generator, a product from Armand Morin, builds directory-style websites for you in a matter of minutes. It is simple to use, it's reliable, it does what it claims to do. The tool is essentially a push-button site builder - all you really have to do is upload the generated pages to your host system. There are no fancy technical skills involved.

Tags

Links

Digg It - UK Finance: Who Makes The Money? Part Two

Related Articles: